ReviewThoracic cancer2023
Recent advances in neoantigen vaccines for treating non-small cell lung cancer.
Review in Thoracic cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 23 citations in OpenAlex.
- Colorectal cancer and tumor vaccines (Review).Oncology letters · 2026Review
- Integrated transcriptomic analysis and machine learning identify immunogenic cell death genes as prognostic markers and therapeutic targets in non-small cell lung cancer.Translational cancer research · 2026Article
- Next generation approaches in cancer immunotherapy targeting mechanisms beyond PD1 and PDL1.Discover oncology · 2026Review
- Nanovaccines for lung cancer: Platforms, mechanistic insights, and translational challenges.Chinese medical journal pulmonary and critical care medicine · 2026Review
- Neoantigen-driven cancer vaccines in personalized oncology: progress, obstacles, and translational prospects.Molecular biology reports · 2026Review
- Perioperative Immunotherapy for Non-Small Cell Lung Cancer (NSCLC).Current oncology reports · 2025Review
- mRNA Vaccines in Modern Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)-A Comprehensive Literature Review with Focus on Current Clinical Trials.Biomedicines · 2025Review
- Identification of neoantigen epitopes in cervical cancer by multi-omics analysis.European journal of medical research · 2025Article
- Evaluation of clinical and safety outcomes of cancer vaccines in patients with advanced non-small cell lung cancer after first-line therapy: a systematic review and meta-analysis.EClinicalMedicine · 2025Article
- Review
- Current Development of Therapeutic Vaccines in Lung Cancer.Vaccines · 2025Review
- The challenge of cytotoxic T cell responses in carcinoma with a focus on lung carcinoma.Frontiers in oncology · 2025Review
- Development of a multi-neoepitope vaccine targeting non-small cell lung cancer through reverse vaccinology and bioinformatics approaches.Frontiers in immunology · 2025Article
- Human interleukin-4-dependent facilitation of human IgG production in PBL-NOG-hIL-4-Tg mice.Frontiers in immunology · 2025Article
- Review
- Seeing the Future of Lung Cancer Vaccination.International journal of molecular sciences · 2024Article
- Analyzing the Spatial Distribution of Immune Cells in Lung Adenocarcinoma.Journal of personalized medicine · 2024Article
- Overcoming Resistance to Checkpoint Inhibitors with Combination Strategies in the Treatment of Non-Small Cell Lung Cancer.Cancers · 2024Review
- Recent advances in neoantigen vaccines for treating non-small cell lung cancer.Thoracic cancer · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The breakthrough of programmed cell death protein 1 (PD-1) blockade therapy has changed the clinical treatment of non-small cell lung cancer (NSCLC) in the past few years. The success of PD-1 blockade therapy has been attributed to high tumor mutation burden and high immunogenicity of lung cancer cells. To further improve the efficacy of NSCLC immunotherapy and overcome the resistance of lung cancer cells to immune checkpoint blockade, new approaches that enhance the active immune response, such as neoantigen vaccines and cellular-based therapies, are urgently required. Neoantigens are considered ideal targets for cancer immunotherapy because of their high immunogenicity and specificity. In this mini review, we first discuss the current advances in neoantigen vaccines for treating cancers and then review the results of preclinical studies and early-phase human clinical trials of neoantigen-based therapies for NSCLC. Finally, we focus on the identification of neoantigens in patients with NSCLC and review the candidate mutations reported by recent studies and our investigations. The review concludes that, in addition to immune checkpoint blockade, approaches targeting neoantigens are promising for improving the efficacy of NSCLC immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.